HTPEP 004
Alternative Names: HTPEP-004Latest Information Update: 24 May 2024
At a glance
- Originator Chengdu Huitai Biomedicine Co
- Class Antifibrotics; Peptides
- Mechanism of Action Thrombospondin 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis
Most Recent Events
- 25 Apr 2024 Preclinical trials in Fibrosis in China (Chengdu Huitai Biomedicine pipeline, April 2024)